Biotech News

Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference

Altimmune (ALT)Altimmune2026-09-03 12:00 ESTConference / presentation

Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in a fireside chat at the Wells Fargo 21 st Annual Healthcare Conference on Thursday, September 10, 2026, at 9:30 a.m. ET.

A webcast of the fireside chat will be available via the Events section of the Altimmune website.

About Altimmune Altimmune is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company’s lead candidate, pemvidutide, is a unique dual-action investigational therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). For more information, please visit www.altimmune.com .

Follow @Altimmune, Inc. on LinkedIn Follow @AltimmuneInc on X

Investor Contact: Luis Sanay, CFA Vice President, Investor Relations ir@altimmune.com

Media Contact: Real Chemistry altimmune@realchemistry.com

Altimmune

Metabolic and Liver Disease Company Altimmune develops pemvidutide for serious metabolic and liver diseases. Balanced Dual Agonist Pemvidutide is a balanced glucagon and GLP-1 receptor agonist intended to combine weight loss with direct effects on liver fat, inflammation, and lipid metabolism. MASH Program The global PERFORMA program is...

Recent company news

ALTAltimmune2026-09-03 12:00 EST

Stock data

Close: 3.24 USD
Market cap: 563.98M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States

Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference

Related news

Mineralys Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference

Altimmune to Present Results of Pemvidutide in MASH in an Oral Presentation and Multiple Poster Presentations at EASL Congress 2026

Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026

Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Aligos Therapeutics to Present at the Cantor Global Healthcare Conference

Sagimet Biosciences to Participate in the Canaccord Genuity 46th Annual Growth Conference

Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference

Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

CVRx to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Altimmune

Recent company news

Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference

Altimmune Announces Second Quarter 2026 Financial Results and Business Update

Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH

Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder

Stock data